Dean T Johnson Net Worth

The estimated Net Worth of Dean T Johnson is at least $320 Thousand dollars as of 5 December 2007. Dean Johnson owns over 1,000 units of Artelo Biosciences Inc stock worth over $23,800 and over the last 22 years Dean sold ARTL stock worth over $296,130.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Dean Johnson ARTL stock SEC Form 4 insiders trading

Dean has made over 11 trades of the Artelo Biosciences Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently Dean sold 1,000 units of ARTL stock worth $12,590 on 5 December 2007.

The largest trade Dean's ever made was exercising 15,000 units of Artelo Biosciences Inc stock on 30 July 2007 worth over $50,250. On average, Dean trades about 5,286 units every 15 days since 2003. As of 5 December 2007 Dean still owns at least 20,000 units of Artelo Biosciences Inc stock.

You can see the complete history of Dean Johnson stock trades at the bottom of the page.

What's Dean Johnson's mailing address?

Dean's mailing address filed with the SEC is , , , , .

Insiders trading at Artelo Biosciences Inc

Over the last 22 years, insiders at Artelo Biosciences Inc have traded over $1,017,062 worth of Artelo Biosciences Inc stock and bought 94,621 units worth $215,565 . The most active insiders traders include Connie Matsui, Steven B Lapin, and Georgia Erbez. On average, Artelo Biosciences Inc executives and independent directors trade stock every 89 days with the average trade being worth of $13,026. The most recent stock trade was executed by Gregory D. Gorgas on 12 August 2022, trading 1,200 units of ARTL stock currently worth $4,800.

What does Artelo Biosciences Inc do?

artelo biosciences is a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics. our programs have the potential to dramatically improve patient care in major markets. with our headquarters team in san diego, california, usa and our european office in dublin, ireland, artelo established a presence in key global biopharma innovation hubs with close access to world-class research expertise. artelo’s research and development leverages the skill, knowledge and experience of our collaboration partners in europe and north america.

Complete history of Dean Johnson stock trades at Artelo Biosciences Inc

Artelo Biosciences Inc executives and stock owners

Artelo Biosciences Inc executives and other stock owners filed with the SEC include:

• Gregory D. Gorgas,
  Pres, CEO, CFO, Treasurer, Sec. & Director
• Jason H. Baybutt,
  Sr. VP of Fin.
• Dr. Steven D. Reich,
  Chief Medical Officer
• Peter Michael O'Brien,
  Sr. VP of European Operations
• Dr. Andrew Yates Ph.D.,
  Sr. VP, Chief Scientific Officer & Member of Scientific Advisor Board
• Randy Schreckhise,
  VP of Fin. & Operations
• Donald T Netter,
  Director
• Brian Schlier,
  Vice President
• James G Tatum,
  Director
• John A Whritner,
  Director
• John L Lahey,
  Director
• Ira R Harkavy,
  Director
• Inc. Lrta,,
  10% owner
• Corp /De/Nasco Holdings, In...,
  
• Steven B Lapin,
  President & COO
• H William Smith,
  V.P., Gen. Counsel & Secretary
• W Phillip Niemeyer,
  Vice President-Prod. Coord.
• Dean T Johnson,
  Chief Financial Officer
• Corp /De/ Geneve,
  10% owner
• John Joseph Crawford,
  Director
• Sharon M Oster,
  Director
• Douglas Blayney,
  Director
• Connie Matsui,
  Director
• Peter Michael O'brien,
  
• Steven Kelly,
  Director
• John W Beck,
  
• Georgia Erbez,
  
• Robert Martin Emanuele,
  Director
• Gregory Reyes,
  Director
• Tamara A Favorito,
  Director
• Gregory D. Gorgas,
  Pres, CEO, CFO, Treas & Sec